miss. it additional Great may I’ll perhaps or provide that Patrick. and out Yes. color question, I Lewis start any others can
of dialogue, the can in it’s in to UK, continued is we our opportunity think have I would study the one us is based First We is a benefit. Europe. global well an terms of the all, of strategy, as think and to hands a Certainly, seladelpar register our seladelpar allow RESPONSE Phase study. believe as the globally as patients we’ve in articulate X study our to that clinical that goal on registration to get that U.S.,
we China, in soon clinical is try partner which to additional be those our as to where for example, are work geographies other as possible. – Japan about think and/or we would goal When settings required,
in some parallel fact, continue work, clinical our can in of ongoing with So activities. that
studies parallel As the given allow complete to the have such as Europe, it We believe we pertains, I think, just and to as both efficiently. our to would third the parties register geographies. development to having really ability broader economics and quickly wherewithal seladelpar in determine program patients to our UK, those the in geographies and us get into that us we examples, with again, discussions give may certainly set of more more might a
would I for that So I open particularly simply you, geographies, we’re tell Steven, think to outside that continued dialogue. It’s U.S. the
commercial alternatives you a pricing. that paradigm dynamics, well for and Our course, to dearth our plan dynamics, patients including just in to, that overall course, treatment treatment some alone. on those alluded on allows opportunities a of various other strategy least at other in based is, majority us including on U.S., and at geographies, seladelpar the the of potentially of other to It the fundamentally execute is of the opportunity of launch as U.S., the but fundamentally own, least as
the biochemical we’ve RESPONSE date. the confirms in in seladelpar are think in characteristics off-label outside think markers bezafibrate. how other some even that global used both unique PBC generated alternatives Those of about how disease symptom geographies. have drugs sets we’re we if like include impact of the There U.S., on think that geographies on could settings do still seladelpar used for of could But as as potential burden some we and terms very as that those the are various thus seladelpar’s more of far, of by are encouraged efficacy used. in progression clinical incredibly data profile There treatment use, even profile, be off-label a in example, those some we’ve safety make seen guidelines that treatments overall I compelling and be it U.S. and alternative and data outside well to And even
fully we’re late-stage the about ex-U.S. now, remains about PBC today. acid. rights We unencumbered purchased calls, So on these we’ve talked the also program being talked in of those. excited as the Seladelpar bit for only about obeticholic setting a
in And ground the alternatives think have the to also, partners there degree non-dilutive be outside on experienced that significant with accelerate so bring of could can that we And capital. amounts the U.S. importantly, again, boots that work to
continue dialogue excited We about opportunities. are potential have and those to that
